Track record · closed signal

Aurinia Pharmaceuticals Inc (AUPH) — closed signal from May 11, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 9, 2026 — +1.2% at the close.

Predicted vs. what happened

AUPH price · publication thesis → realized outcomesplit-adjusted

$15.20 – $15.80Entry zone — fair-value band

$15.66Published — price the day we called it

$17.07Target — the price the thesis aimed for

$19.25Peak — highest point inside the window, not a realized return

$15.85Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 42 days.

At window close

+1.2%

realized, from the publication price to the last close inside the window

Peak gain

+22.9%

peak, from the publication price — not a realized return

S&P 500, same window

+4.9%

SPY over the identical days, dividend-adjusted

Window close

$15.85

last close inside the window, ended August 9, 2026

Peak price

$19.25

peak on June 24, 2026 — not a realized return

Days to target

The thesis — published May 11, 2026

Predicted growth

+9%

over the measurement window

Target price

$17.07

the price the thesis aimed for

Entry zone

$15.20 – $15.80

the fair-value band we waited for

Price at publication

$15.66

published May 11, 2026

Confidence

78%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Aurinia looks safer on the downside: it makes money, has enough cash, and insiders are buying, while price action has been beaten down. The concern is weak catalyst: recent headlines aren't specific to the company, so the case depends more on future earnings than new news. The technical picture is still weak, so this reads as a recovery setup rather than a confirmed uptrend.

Primary drivers

Cash on hand lowers need for new financing
Insider buying aligns management with shareholders
Earnings have come in better than expected
Limited company-specific news raises catalyst risk

How it played out

AUPH: target reached in 42 days

Lyra published a recovery thesis at $15.66 and expected 9% growth. The thesis pointed to cash on hand, insider buying, and earnings that had beaten expectations. It also flagged limited company-specific news and weak price action as risks.

The stock reached the $17.07 target in 42 days. It later peaked at $19.25 on June 24, a 22.9% gain. By the end of the window, it was back at $15.85. The thesis played out within the measured period, although most of the rise had faded by the close.

What happened during the window

On August 6, 2026, Aurinia reported second-quarter total revenue of $83.2 million and net income of $37.4 million. It also reiterated 2026 total revenue guidance of $315 million to $325 million.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AUPH signals